Form 4: Immuneering Corp Director Ann Berman Granted Stock Options

Immuneering Corp Director Ann E. Berman was granted 33,350 stock options with an exercise price of $1.90, vesting over one year starting July 13, 2025.

Summary

• Ann E. Berman, a Director of Immuneering Corp (IMRX), was granted 33,350 stock options.
• The options have an exercise price of $1.90 per share.
• The grant date for these options was June 13, 2025.
• The options will vest in equal monthly installments over a one-year period, commencing on July 13, 2025.
• Full vesting is expected by June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever occurs first.
• The options have an expiration date of June 13, 2035.
• Following this transaction, Ms. Berman beneficially owns 33,350 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice to align interests, indicating a neutral to slightly positive sentiment as it incentivizes long-term performance without immediate negative implications for the company's financial health.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• No immediate cash inflow to the company from the grant itself, as the price of the derivative security is $0.

Risks

• Potential future dilution of existing shares if the granted stock options are exercised.

Future Outlook

The stock options granted to Director Ann E. Berman are set to vest in equal monthly installments over a one-year period, commencing on July 13, 2025, and will be fully vested by June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever is earlier. The options have an expiration date of June 13, 2035.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, a common practice across various industries, including biotechnology, to align management and board interests with shareholder value creation. Such grants are standard mechanisms for incentivizing long-term commitment and performance.

Related Party Transactions

• The grant of 33,350 stock options to Ann E. Berman, a Director of Immuneering Corp, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value due to aligned director incentives.
• Management/Directors: Ann E. Berman directly benefits from the equity grant, providing a long-term incentive.

Next Steps

• The stock options will begin vesting in equal monthly installments starting July 13, 2025.
• The options will be fully vested by June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.

Key Dates

Keywords

Immuneering Corp, IMRX, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Executive Compensation, Biotechnology